A Study of TAK-071 in People With Parkinson Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

October 21, 2020

Primary Completion Date

February 27, 2023

Study Completion Date

February 27, 2023

Conditions
Parkinson DiseaseHealthy Participants
Interventions
DRUG

TAK-071

TAK-071 tablet.

DRUG

Placebo

TAK-071 placebo-matching tablet.

Trial Locations (21)

14618

University of Rochester Medicine - Movement Disorders Unit, Rochester

19107

University of Philadelphia, Philadelphia

23502

Meridian Clinical Research, Norfolk

29425

Medical University of South Carolina - PPDS, Charleston

30912

Augusta University, Augusta

32806

PPD Phase 1 Clinic, Orlando

33351

Infinity Clinical Research, LLC, Sunrise

33612

USF Medical Clinic, Tampa

45459

Neurology Diagnostics, Inc. - ERG - PPDS, Dayton

46202

Indiana University Health Neuroscience Center, Indianapolis

48334

Quest Research Institute - Hunt - PPDS, Farmington Hills

55427

Park Nicollet Health Services, Golden Valley

60611

Feinberg School of Medicine Northwestern University, Chicago

77030

Baylor College of Medicine, Houston

78681

Central Texas Neurology, Round Rock

80113

Rocky Mountain Movement Disorders Center, Englewood

90048

Cedars Sinai Medical Center, Los Angeles

92697

University of California Irvine Medical Center, Irvine

92845

Collaborative Neuroscience Network, LLC, Garden Grove

98034

Evergreen Hospital Medical Center, Kirkland

99202-6290

Inland Northwest Research, Spokane

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Michael J. Fox Foundation for Parkinson's Research

OTHER

lead

Takeda

INDUSTRY

NCT04334317 - A Study of TAK-071 in People With Parkinson Disease | Biotech Hunter | Biotech Hunter